< PreviousEXHIBITION GUIDE – ECCVID 202040 Exhibitor/Sponsor Profiles AstraZeneca PLC 1 Francis Crick Avenue Cambridge, CB2 0RE United Kingdom www.astrazeneca.com Respiratory & Immunology is one of AstraZeneca’s three therapy areas and is a key growth driver for the Com- pany. AstraZeneca is an established leader in respiratory care, and its inhaled and biologic medicines reached more than 53 million patients in 2019. Building on a 50-year heritage, the Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death. The Company’s early respiratory research is focused on emerging science involving immune mechanisms, lung damage and abnormal cell repair processes in disease and neuronal dysfunction. VACCINE DEVELOPMENTS AND TRIALS DRUG DEVELOPMENT AND TREATMENT MODALITIES (INCL. CLINICAL TRIALS)EXHIBITION GUIDE – ECCVID 202041 Exhibitor/Sponsor Profiles Baxter ICNET 1210 Lansdowne Court Gloucester Business Park Gloucester, Gloucestershire, GL3 4AB United Kingdom www.icnetsoftware.com ICNET Clinical Surveillance Platform The ongoing COVID-19 pandemic has presented even the most developed and efficient healthcare systems with unprecedented challenges as they’ve had to adapt quickly to manage its suppression. Now more than at any other time, technology is playing a crucial role with healthcare systems adjusting to new models. Tools supporting efficiencies, rapid intervention, remote working and remote collaboration are becoming increasingly important. ICNET National Suite supports public health communicable disease professionals at the mass population level, while ICNET Hospital Suite supports infection prevention professionals within the healthcare facility setting. To learn more, visit our virtual booth. www.icnetsoftware.com INFECTION CONTROL PREPAREDNESS AND RESPONSEEXHIBITION GUIDE – ECCVID 202042 BD 11 rue aristide Berges 38801 Le pont de Claix France www.bd.com BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, di- agnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD has 65,000 employees and a pres- ence in virtually every country around the world to address some of the most chal- lenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. DIAGNOSTICS EPIDEMIOLOGY - LOCAL, REGIONAL, GLOBAL AND DIAGNOSTICS Exhibitor/Sponsor ProfilesEXHIBITION GUIDE – ECCVID 202043 Exhibitor/Sponsor Profiles Beckman Coulter Rue Juste-Olivier 22 PO Box 1059 1260 Nyon Switzerland www.beckman.com As the SARS-CoV-2 pandemic contin- ues, Beckman Coulter Life Sciences has a firm commitment to enabling our customers to gain a better under- standing of this disease and advance much-needed discoveries. For this reason, we compiled relevant resources and tools to support and fa- cilitate your COVID-19 research. Learn more about our workflow solutions for: • Understanding the Immune Response • Viral Isolation & Characterization DIAGNOSTICS EPIDEMIOLOGY - LOCAL, REGIONAL, GLOBAL AND DIAGNOSTICS VACCINE DEVELOPMENTS AND TRIALS INFECTION CONTROL PREPAREDNESS AND RESPONSE BASIC SCIENCE AND VIROLOGY IMMUNE RESPONSE, IMMUNOMODULATIONEXHIBITION GUIDE – ECCVID 202044 bioMérieux SA Chemin de l’Orme 69280 Marcy l’Etoile France www.biomerieux.com A world leader in microbiology, spe- cialized in immunoassays and leading pioneer in syndromic molecular test- ing, bioMerieux provides diagnostic solutions (systems, reagents, software, services) to answer major public health issues such as antibiotic resistance, sepsis and respiratory infections, includ- ing COVID-19. bioMerieux operates in 44 countries and serves over 160 countries through its distributors. bioMerieux’s COVID-19 offer comprises the new BioFire® Respiratory 2.1 plus Panel for the Syndromic Testing solution, the All-in-one ARGENE® SARS-COV-2 R-GENE® real-time PCR assay and the VIDAS® SARS-COV-2 immunoassay for the rapid detection of lgM & lgG antibodies. DIAGNOSTICS EPIDEMIOLOGY - LOCAL, REGIONAL, GLOBAL AND DIAGNOSTICS Exhibitor/Sponsor ProfilesEXHIBITION GUIDE – ECCVID 202045 Exhibitor/Sponsors Profiles Bio-Rad 3, boulevard Raymond Poincaré 92430 Marnes-la-Coquette France www.bio-rad.com Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in devel- oping, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on qual- ity and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research in- stitutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 8,000 em- ployees worldwide. DIAGNOSTICS EPIDEMIOLOGY - LOCAL, REGIONAL, GLOBAL AND DIAGNOSTICSEXHIBITION GUIDE – ECCVID 202046 Copan Via Francesco Perotti 10 25125 Brescia Italy www.copangroup.com Copan is dedicated to developing and providing high quality and cut- ting-edge biological sample collection products for infectious diseases, hu- man genomics, environmental and forensic applications, along with automated workflow solutions. Decades of experience and leadership in the pre-analytics field resulted in the development of numerous solutions tailored to fit any need: our patented products FLOQSwabs®, eSwab® and LBM® already revolutionized the collection and transport processes and our modular lab automation systems, WASP® and WASPLab®, eased healthcare professionals workflow. Today Copan is still eager to continue this innovation, providing quality products, customized services and prime solutions to improve the health and wellness of patients. Visit our booth to learn more about us! Exhibitor/Sponsors Profiles DIAGNOSTICS EPIDEMIOLOGY - LOCAL, REGIONAL, GLOBAL AND DIAGNOSTICS PRE-ANALYTICSEXHIBITION GUIDE – ECCVID 202047 Exhibitor/Sponsors Profiles Correvio Place des Alpes 2-4 1201 Geneva Switzerland www.correvio.com Correvio, now a wholly-owned subsid- iary of ADVANZ PHARMA, is a special- ty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. Correvio’s com- mercial presence is focused on major European markets with a broader distribution network covering more than 60 countries worldwide. Correvio’s licensed anti-infective medicines include XYDALBA™ (dalbavancin hydrochloride), and ZEVTERA®/MABELIO® (ceftobiprole medocaril) for select European markets and Israel. DRUG DEVELOPMENT AND TREATMENT MODALITIES (INCL. CLINICAL TRIALS)EXHIBITION GUIDE – ECCVID 202048 Gilead 2 Roundwood Avenue UB11 1AF Uxbridge United Kingdom www.gilead.com Gilead Sciences is a research-based biopharmaceutical company that dis- covers, develops and commercializes innovative medicines in areas of un- met medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California, USA. For more information, please visit www.gilead.com Exhibitor/Sponsors Profiles VACCINE DEVELOPMENTS AND TRIALS DRUG DEVELOPMENT AND TREATMENT MODALITIES (INCL. CLINICAL TRIALS)EXHIBITION GUIDE – ECCVID 202049 Illumina 19 Granta Park, Great Abington Cambridge, Cambridgeshire CB21 6DF, United Kingdom www.illumina.com For more than 20 years, Illumina has aspired to improve human health by unlocking the power of the genome. Now, with more than 3400 patents worldwide and our sequencing-by- synthesis technology being used to generate over 90% of the world’s sequencing data, we are just beginning to discover the true impact of genomics and whole-genome sequencing. This realization, and the discoveries we know lie ahead, are what inspire us to push the boundaries of our imagination, drive innovation, and offer solutions across the genomic spectrum. Exhibitor/Sponsors Profiles DIAGNOSTICS EPIDEMIOLOGY - LOCAL, REGIONAL, GLOBAL AND DIAGNOSTICS INFECTION CONTROL PREPAREDNESS AND RESPONSENext >